Clinical significance of tumor-infiltrating lymphocytes in breast cancer

SE Stanton, ML Disis - Journal for immunotherapy of cancer, 2016 - Springer
Tumor infiltrating lymphocytes (TIL) play an essential role in mediating response to
chemotherapy and improving clinical outcomes in all subtypes of breast cancer. Triple …

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

P Savas, R Salgado, C Denkert, C Sotiriou… - Nature reviews Clinical …, 2016 - nature.com
The clinical relevance of the host immune system in breast cancer has long been
unexplored. Studies developed over the past decade have highlighted the biological …

Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection

BD Lehmann, B Jovanović, XI Chen, MV Estrada… - PloS one, 2016 - journals.plos.org
Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into
distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat …

Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study

R Nanda, LQM Chow, EC Dees, R Berger… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer
strategy. Several lines of evidence support the study of immunotherapy in triple-negative …

Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study

HR Ali, L Chlon, PDP Pharoah, F Markowetz… - PLoS …, 2016 - journals.plos.org
Background Immune infiltration of breast tumours is associated with clinical outcome.
However, past work has not accounted for the diversity of functionally distinct cell types that …

Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review

SE Stanton, S Adams, ML Disis - JAMA oncology, 2016 - jamanetwork.com
Importance The presence of tumor-infiltrating lymphocytes (TILs) is a favorable prognostic
factor in breast cancer, and TILs may synergize with chemotherapy and immune checkpoint …

Triple-negative breast cancer: treatment challenges and solutions

J Collignon, L Lousberg, H Schroeder… - Breast Cancer: Targets …, 2016 - Taylor & Francis
Triple-negative breast cancers (TNBCs) are defined by the absence of estrogen and
progesterone receptors and the absence of HER2 overexpression. These cancers represent …

RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD …

S Loi, S Dushyanthen, PA Beavis, R Salgado… - Clinical Cancer …, 2016 - AACR
Purpose: Tumor-infiltrating lymphocytes (TIL) in the residual disease (RD) of triple-negative
breast cancers (TNBC) after neoadjuvant chemotherapy (NAC) are associated with …

Biology and management of patients with triple-negative breast cancer

P Sharma - The oncologist, 2016 - academic.oup.com
Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is
associated with poor long-term outcomes compared with other breast cancer subtypes …

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas

A Cimino-Mathews, E Thompson, JM Taube, X Ye… - Human pathology, 2016 - Elsevier
Programmed death ligand 1 (PD-L1) expression by tumor-infiltrating lymphocytes (TILs) and
tumor cells in breast cancer has been reported, but the relationships between PD-L1 …